From Strategy To Submission: End-To-End Clinical, Biometrics, And Regulatory Support In Neurology

A successful NDA requires more than strong clinical data; it demands seamless coordination across biometrics, regulatory, medical writing, and operational teams. For a biopharmaceutical company developing a first-in-class CNS therapy, Veristat served as an integrated development partner, guiding the program from Phase 3 execution through NDA submission and FDA approval. Veristat’s multidisciplinary team delivered end-to-end NDA solutions, including biostatistics and programming, regulatory strategy, medical writing, CDISC data migration, publishing, and project management. By leading complex data integration efforts and aligning efficacy and safety narratives across studies, Veristat transformed fragmented data and processes into a cohesive, submission-ready package.

Veristat's team helped accelerate NDA readiness by coordinating multiple vendors, streamlining decision-making, and ensuring every deliverable supported a unified regulatory strategy. This case study highlights the resulting on-time submission, approval without major queries, and a continued partnership supporting future development programs.